Search

Your search keyword '"Tsai, S.‐F."' showing total 275 results
Start Over Author "Tsai, S.‐F."
275 results on '"Tsai, S.‐F."'

13. Novel ADAR1 mutations in three cases of psoriasis coexisting with dyschromatosis symmetrica hereditaria.

Author

Weng, H.‐Y., Wu, R.‐W., Chen, Y.‐T., Lin, Y.‐F., Liu, Y.‐M., Tsai, S.‐F., and Chang, C.‐H.

Subjects
GENETIC mutation, VITILIGO, PSORIASIS, PSORIATIC arthritis, TYPE I interferons, SYMPTOMS
Abstract

We here report three cases with RNA-specific adenosine deaminase ( I ADAR1 i ) mutations causing psoriasis concomitant with dyschromatosis symmetrica hereditaria (DSH). Co-existence of psoriasis and DSH implies that patients with I ADAR1 i mutations may have decreased A-to-I RNA editing in keratinocytes, leading to the development of psoriasis. [Extracted from the article]

Published
2022
Full Text
View/download PDF

15. Is Initiating NOACs for Atrial Arrhythmias Safe in Adults with Congenital Heart Disease?

Author

Yang, Hayang, Bouma, Berto J., Mulder, Barbara J M, Heidendael, J. F., Veen, G., Konings, Thelma C, Sieswerda, G. T.J., Meijboom, F. J., Post, M. C., van Dijk, A., Budts, W., Morissens, M., Ladouceur-Wodzak, Michelle, Tobler, D., Schwerzmann, M., Rutz, T., Bouchardy, J., Greutmann, M., Scognamiglio, G., Skoglund, K., Christersson, C., Gumbiene, L., Laukyte, M., Khairy, P., Aboulhosn, J., Veldtman, G., Webb, G., Broberg, C. S., Opotowsky, A. R., Shafer, K., Tsai, S. F., Moe, T., Niwa, K., Mizuno, A., Cardiology, ACS - Heart failure & arrhythmias, ACS - Atherosclerosis & ischemic syndromes, University of Zurich, Mulder, Barbara J M, Gumbienė, Lina, Laukytė, M., ACS - Amsterdam Cardiovascular Sciences, APH - Personalized Medicine, APH - Aging & Later Life, Other departments, and ACS - Pulmonary hypertension & thrombosis

Subjects
Male, Congenital heart disease, Atrial arrhythmia, Anticoagulation, Non vitamin K antagonist oral anticoagulant, Heart disease, Administration, Oral, 030204 cardiovascular system & hematology, 0302 clinical medicine, 2736 Pharmacology (medical), Medicine, Pharmacology (medical), 030212 general & internal medicine, Prospective Studies, Registries, Prospective cohort study, Thromboembolic event, General Medicine, Middle Aged, 3004 Pharmacology, 10209 Clinic for Cardiology, Cardiology, Registry data, Female, Cardiology and Cardiovascular Medicine, Major bleeding, Adult, Heart Defects, Congenital, medicine.medical_specialty, Short Communication, 610 Medicine & health, Hemorrhage, 2705 Cardiology and Cardiovascular Medicine, 03 medical and health sciences, Internal medicine, Thromboembolism, Humans, In patient, cardiovascular diseases, Adverse effect, Pharmacology, business.industry, Bleeding, Anticoagulants, Arrhythmias, Cardiac, Atrial arrhythmias, medicine.disease, Observational study, business
Abstract

Background In recent years, non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have been increasingly prescribed to adults with congenital heart disease (CHD) and atrial arrhythmias without good evidence for either safety or efficacy. To address this gap, we initiated an ongoing prospective global registry (NOTE: non-vitamin K antagonist oral anticoagulants for thromboembolic prevention in patients with congenital heart disease). Using the NOTE registry data, the present study aimed to evaluate the occurrence of any adverse events during the initiation phase (first 30 days) of NOACs in adults with CHD and atrial arrhythmias. Methods and Results For this prospective observational study, 99 adults with CHD and atrial arrhythmias (median age 49 years [IQR 38-61], 53% male) who initiated NOACs at or after the inclusion point were analysed. Thromboembolic events, major bleeding and other minor adverse events were assessed after the first 30 days since the initiation of NOACs. In 54 patients transitioning from VKA to NOACs, 8 minor adverse events (5 minor bleeding; 3 side-effects; 1 drop-out due to minor bleeding) occurred within 30 days after the transition. No adverse events were reported in 46 VKA-naive patients within 30 days after the initiation of NOACs. Conclusions Initiation of NOACs and transition from VKA to NOACs seem to be safe during the first month, without major adverse events and with only limited minor side effects in adults with CHD and atrial arrhythmias. This global ongoing prospective registry enables precise collection of important clinical information in real-world adults with CHD, managed with NOACs. Electronic supplementary material The online version of this article (doi:10.1007/s10557-017-6745-y) contains supplementary material, which is available to authorized users.

Published
2017

28. Final report on APMP.T-K7 key comparison of water triple point cells

Author

Tsai, S F, primary, White, R, additional, Tamba, J, additional, Yamazawa, K, additional, Ho, M K, additional, Tsui, C M, additional, Zaid, G, additional, Achmadi, A, additional, Gam, K S, additional, Othman, H, additional, Ali, N M, additional, Yuan, K H, additional, Shaochun, Y, additional, Liedberg, H, additional, and Yaokulbodee, C, additional

Published
2016
Full Text
View/download PDF

30. Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: Molecular epidemiology and genome evolution

Author

Yeh, S.-H., Wang, H.-Y., Tsai, C.-Y., Kao, C.-L., Yang, J.-Y., Liu, H.-W., Su, I.-J., Tsai, S.-F., Chen, D.-S., Chen, P.-J., Lee, Y.-T., Teng, C.-M., Yang, P.-C., Ho, H.-N., Chang, M.-F., Wang, J.-T., Chang, S.-C., Wang, W.-K., Hsiao, C.-H., and Hsueh, P.-R.

Subjects
Genome evolution, Lineage (genetic), viruses, Molecular Sequence Data, Taiwan, Genome, Viral, Biology, medicine.disease_cause, Severe Acute Respiratory Syndrome, Genome, Polymerase Chain Reaction, Evolution, Molecular, medicine, Humans, Base Pairing, Phylogeny, Coronavirus, Genetics, Multidisciplinary, Molecular epidemiology, Base Sequence, Transmission (medicine), Outbreak, Biological Sciences, Virology, Severe acute respiratory syndrome-related coronavirus, Viral evolution, DNA, Viral, Mutation, RNA, Viral
Abstract

Since early March 2003, the severe acute respiratory syndrome (SARS) coronavirus (CoV) infection has claimed 346 cases and 37 deaths in Taiwan. The epidemic occurred in two stages. The first stage caused limited familial or hospital infections and lasted from early March to mid-April. All cases had clear contact histories, primarily from Guangdong or Hong Kong. The second stage resulted in a large outbreak in a municipal hospital, and quickly spread to northern and southern Taiwan from late April to mid-June. During this stage, there were some sporadic cases with untraceable contact histories. To investigate the origin and transmission route of SARS-CoV in Taiwan's epidemic, we conducted a systematic viral lineage study by sequencing the entire viral genome from ten SARS patients. SARS-CoV viruses isolated from Taiwan were found closely related to those from Guangdong and Hong Kong. In addition, all cases from the second stage belonged to the same lineage after the municipal hospital outbreak, including the patients without an apparent contact history. Analyses of these full-length sequences showed a positive selection occurring during SARS-CoV virus evolution. The mismatch distribution indicated that SARS viral genomes did not reach equilibrium and suggested a recent introduction of the viruses into human populations. The estimated genome mutation rate was ≈0.1 per genome, demonstrating possibly one of the lowest rates among known RNA viruses.

Published
2004

31. Serum Adipokine Levels in Renal Transplant Recipients

Author

Shu, K.-H., primary, Wu, M.-J., additional, Chen, C.-H., additional, Cheng, C.-H., additional, Yu, T.-M., additional, Chuang, Y.-W., additional, Huang, S.-T., additional, Tsai, S.-F., additional, Lo, Y.-C., additional, Weng, S.-C., additional, Wen, M.-C., additional, and Ho, H.-C., additional

Published
2014
Full Text
View/download PDF

34. Reduced Variability of Tacrolimus Trough Level in Once-Daily Tacrolimus-Based Taiwanese Kidney Transplant Recipients With High-Expressive Genotype of Cytochrome P450 3A5

Author

Wu, M.-J., primary, Chang, C.-H., additional, Cheng, C.-Y., additional, Shu, K.-H., additional, Chen, C.-H., additional, Cheng, C.-H., additional, Yu, T.-M., additional, Chuang, Y.-W., additional, Huang, S.-T., additional, Tsai, S.-F., additional, Ho, H.-C., additional, Li, J.-R., additional, Shiu, Y.-N., additional, and Fu, Y.-C., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results